support@mellalta.com   +1 (304) 470-2225

Adoptive TCR Therapy -A Revolution in Immuno-oncology Therapeutic Modality

Adoptive T-cell therapy is one potentially groundbreaking treatment for cancer that genetically alters natural T cells to make them tumor-specific and to improve their ability to destroy tumor cells. The genetically modified T cells are able to express chimeric […]

Read More

Coronavirus (COVID-19) Update: FDA Issues Guidance for Conducting Clinical Trials

The FDA recognizes that the COVID-19 pandemic can affect the conduct of clinical trials on medical products, including drugs, devices and biological products. Challenges may arise, for example, from quarantine, site closures, travel restrictions, supply […]

Read More

Perhaps anti-TFPI no longer a feasible strategy for Hemophilia-Novo Nordisk suspended three TFPI trials

The discovery and characterization of the anticoagulant protein factor pathway inhibitor (TFPI) has led to the realization that inhibiting TFPI activity could restore functional hemostasis through the extrinsic pathway of blood clotting in a way […]

Read More

Get In Touch

Let's keep the conversation going